Muscle Relaxant Drugs Market Size (2024 - 2029)

The muscle relaxant drugs market is projected to experience growth driven by an increasing geriatric population and a rising prevalence of musculoskeletal disorders. The demand for these drugs has been influenced by their effectiveness in managing conditions exacerbated by the COVID-19 pandemic, although this demand is expected to stabilize as pandemic-related cases decline. The introduction of new products by key market players further supports market expansion. Despite these growth drivers, the market faces challenges due to the potential side effects associated with muscle relaxant drugs.

Market Size of Muscle Relaxant Drugs Industry

Muscle Relaxant Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Muscle Relaxant Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Muscle Relaxant Drugs Market Analysis

The muscle relaxant drugs market is expected to register a CAGR of 5.6% over the forecast period.

The COVID-19 pandemic significantly impacted the growth of the muscle relaxant drug market. For instance, an article published in Perspectives in Psychiatric Care in March 2021 reported that muscle relaxants effectively reduced anxiety and improved the sleep quality of patients with COVID-19. The article also said that healthcare professionals administered progressive muscle relaxants to patients with COVID-19. Thus, COVID-19 increased the demand for muscle relaxants. However, in the current scenario, it is anticipated that with the decrease in COVID-19 cases, the need for muscle relaxants may get stabilized as compared to the beginning of the pandemic, but the increase in the prevalence of various musculoskeletal disorders is expected to increase the demand for muscle relaxants over the forecast period.

The factors driving the growth of the studied market include rising geriatric populations worldwide and the increase in musculoskeletal disorders. For instance, in 2021, an article published by the Work-Related Musculoskeletal Disorders statistics in Great Britain in 2021 stated that 470,000 people had work-related musculoskeletal disorders who were new or long-standing in the year 2020-2021. In the future, these conditions are expected to worsen and need external help, thereby accelerating market growth.

Similarly, an article published in the journal Annals of Medicine Surgery in December 2021 reported that a survey conducted among 342 doctors working in the operating room in a hospital in North-West Ethiopia in the year 2021 said the prevalence of work-related musculoskeletal disorders was 64.2% among healthcare providers. Thus, the high prevalence of musculoskeletal disorders is expected to increase the demand for muscle relaxant drugs, contributing to the market's growth. Additionally, the increasing prevalence of pain and spasm conditions among the global population and a rising focus on developing novel drugs for treating spasms and pain are other factors bolstering market growth.

Moreover, the increasing geriatric population is driving the demand for muscle relaxants as musculoskeletal disorders are more prevalent in an older population, so muscle relaxants are mainly used to reduce the pain and symptoms associated with these diseases and thus drive the growth of the studied market. For instance, in 2022, United Nations Projections reported that in 2022, there were 771 million people aged 65 years or over globally, and this number is projected to reach 994 million by 2030 and 1.6 billion by 2050. Thus, the increasing geriatric population is more commonly using muscle relaxants, increasing its demand and thus driving the growth of the studied market.

Furthermore, the new product launches by various key market players are expected to drive growth. For instance, in July 2021, Hikma Pharmaceuticals launched a Succinylcholine Chloride injection, USP 20 mg/ml, in the United States. Succinylcholine Chloride Injection, USP was used in the treatment of COVID-19 patients. In addition to general anesthesia, it is indicated to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. Thus, due to the growing geriatric population, increasing prevalence of musculoskeletal disorders, and new product launches, the market is expected to grow significantly over the forecast period. However, side effects associated with muscle relaxant drugs are acting as a restraining factor to the market growth.

Muscle Relaxant Drugs Industry Segmentation

As per the scope of the report, muscle relaxants are a distinct group of medications used to relax or reduce tension in the muscle. Baclofen, methocarbamol, and tizanidine are the few muscle relaxant drugs that work in the brain or spinal cord to block over-excited neuronal pathways. The Muscle Relaxant Drugs Market is segmented by Type of Drugs (Facial Muscle Relaxants, Skeletal Muscle Relaxants, and Neuromuscular Blocking Agents), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type of Drugs
Facial Muscle Relaxants
Skeletal muscle Relaxants
Neuromuscular Blocking Agents
By Dristibution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Muscle Relaxant Drugs Market Size Summary

The muscle relaxant drugs market is poised for significant growth, driven by factors such as the increasing prevalence of musculoskeletal disorders and a rising geriatric population. The demand for muscle relaxants has been bolstered by the COVID-19 pandemic, which highlighted their efficacy in reducing anxiety and improving sleep quality among patients. As the pandemic's impact stabilizes, the focus shifts to the growing need for muscle relaxants due to the escalating incidence of musculoskeletal conditions. The market is further supported by the development of novel drugs aimed at alleviating pain and spasms, alongside the introduction of new products by key players. Despite the potential for growth, the market faces challenges from the side effects associated with muscle relaxant drugs.

In North America, the muscle relaxant drugs market is experiencing robust expansion, attributed to the high prevalence of musculoskeletal disorders and a substantial geriatric population. The region benefits from regulatory approvals and the presence of numerous market players, which contribute to the market's dynamic nature. The increasing number of surgical procedures necessitating neuromuscular blocking agents also fuels market growth. Additionally, funding for the development of advanced muscle relaxant drugs is expected to further propel the market. The competitive landscape is characterized by a fragmented market with several global and regional companies, including prominent names like Pfizer, Teva Pharmaceuticals, and Abbvie Inc., actively participating in market activities.

Explore More

Muscle Relaxant Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Geriatric Population

      2. 1.2.2 Increasing Prevalence of Musculoskeletal Disorders

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects of Muscle Relaxants

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type of Drugs

      1. 2.1.1 Facial Muscle Relaxants

      2. 2.1.2 Skeletal muscle Relaxants

      3. 2.1.3 Neuromuscular Blocking Agents

    2. 2.2 By Dristibution Channel

      1. 2.2.1 Hospital Pharmacy

      2. 2.2.2 Retail Pharmacy

      3. 2.2.3 Online Pharmacy

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Muscle Relaxant Drugs Market Size FAQs

The Muscle Relaxant Drugs Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)

Pfizer, Teva Pharmaceuticals, Zydus Cadila, Ipsen Biopharmaceuticals Inc. and Neurana Pharmaceuticals are the major companies operating in the Muscle Relaxant Drugs Market.

Muscle Relaxant Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)